Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes

Yan, Huzheng; Luo, Ma; Wang, Lifei; Qiu, Zhenkang; Mo, Zhiqiang; Xiang, Zhanwang; Zhang, Yanling; Chen, Guan-Yu; Zhong, Zhihui; Wang, Xiuchen; Gao, Fei; Zhang, Fujun

doi:10.1186/s40644-020-00299-x

Cited by 8 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, D90 and OAR doses are often used as important technical parameters in 125 I brachytherapy, and the univariate analysis showed that patients with higher D90 (≥ 110 Gy) and lower OAR (< 4.5 Gy) of OBMs had a signi cant local tumor control. This is in line with clinical practice, where the planned dose and alignment of intraoperative seeds are reduced for a safe dose range for target lesions adjacent to more important tissues and organs, which in turn leads to challenging technical implementation, insu cient dose, and coverage of the target lesion [33]. It follows that better preoperative planning is particularly important to improve the e cacy of 125 I brachytherapy for OEMs.…”

Section: Discussionsupporting

confidence: 67%

125I brachytherapy: a useful treatment to control painful osteogenic bone metastases

Liu

Jiao

et al. 2022

Preprint

View full text Add to dashboard Cite

Backgrounds: 125I brachytherapy is effective in relieving cancer pain due to osteolytic bone metastases. However, fewer studies focused on painful osteogenic bone metastases (OBMs), we conducted a retrospective study to evaluate the efficacy of 125I brachytherapy for the treatment of painful OBMs.Methods: From April 2017 to April 2019, 65 patients of OBMs were treated with CT/Cone-beam CT (CBCT)-guided 125I brachytherapy. Technical success, visual analog scale scores (VAS), daily morphine consumption (DMC), relief of pain (RoP), quality of life (QoL), local tumor control (LCR), progression-free survival (PFS), and overall survival (OS) were recorded and analyzed. The Logistic regression analysis and the Cox regression models were performed to predict RoP and the PFS, respectively. Results: Technical success rates were 100%. VAS and DMC continuously decreased significantly at 2 weeks, 6 weeks, and 10 weeks (all P<0.05). The RoP at 6 weeks was 84.62%. QoL including sleep, appetite, spiritual state, and fatigue showed improvement at 6 and 10 weeks. LCR was 100% at 10 weeks. The PFS and OS were 10.40 and 29.80 months, respectively. Two factors were significantly associated with the RoP: max diameter (MD< 3 cm vs. ≥ 3 cm, P=0.028) and serum levels of bone alkaline phosphatase (B-ALP) (< 100 U/L vs. ≥ 100 U/L, P=0.038). Three independent risk factors were identified for PFS: D90 < 110 Gy (HR 2.89, P=0.012), B-ALP ≥ 100 U/L (HR 3.39, P=0.009), and MD ≥ 3 cm (HR 5.86, P=0.005). Conclusions: 125I brachytherapy is an effective treatment in relieving painful OBMs and improving patients’ QoL.

show abstract

Section: Discussionsupporting

confidence: 67%

125I brachytherapy: a useful treatment to control painful osteogenic bone metastases

Liu

Jiao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…125 I brachytherapy is associated with only minor complications. Our previous study reported no deaths or severe complications in patients who underwent 125 1 brachytherapy [ 21 ]. Although 17 cases appeared with minor complications (such as fever and pain) and five patients developed self-limiting pneumothorax in our study, all recovered after symptomatic treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The CT-guided 125 I brachytherapy procedure was described in our previously published literature [ 21 ]. Based on the preoperative enhanced computerized tomography (CT) or magnetic resonance imaging (MRI), clinical target volume (CTV), planned target volume (PTV), and puncture path were delineated by the physicist (Fig.…”

Section: Methodsmentioning

confidence: 99%

Clinical efficacy of CT-guided 125I brachytherapy in patients with local residual or recurrent hepatocellular carcinoma after thermal ablation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objectives Treatment methods of local residual or recurrent hepatocellular carcinoma (HCC) after thermal ablation are limited. Therefore, our study aimed to explore the efficacy and prognostic factors of 125I brachytherapy for local residual or recurrent lesion after thermal ablation. Methods A total of 114 patients with 212 local residual or recurrent HCC tumors after thermal ablation underwent 125I brachytherapy. Local progression-free survival (LPFS) and prognostic factors were analyzed by Kaplan–Meier curves and the Cox model. Results After a 6-month follow-up, the percentage of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) was 57%, 13.2%, and 5.2%, respectively. The 1-, 2-, and 3-year LPFS rates were 58.7%, 50.0%, and 41.2%, respectively. Portal vein tumor thrombus (PVTT) (p = 0.03), the number of intrahepatic tumors (p = 0.01), and AFP level (p = 0.02) were independent risk factors for local tumor progression (LTP). The median LPFS in patients without PVTT (22 months) was much longer compared to those with PVTT (10 months). The median LPFS in patients with less than three intrahepatic lesions improved from 17 to 24 months. The median LPFS was only 5 months in the high AFP group, but was prolonged with a decrease in AFP level (24 months). No severe complications were recorded. All complications were controllable and treatable. Conclusions CT-guided 125I brachytherapy was a safe and effective treatment for patients with local residual or recurrent HCC after thermal ablation to improve local control rate.

show abstract

“…Radioactive iodine-125 ( 125 I) seed implantation (RISI) is one of the most promising methods of brachytherapy, which has the advantages of minimally invasive, high local dose, sustained killing of tumors, and relative safety to surrounding normal tissue [ 4 ]. It was initially applied to prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and prognostic factors of CT-guided radioactive iodine-125 seed implantation for the treatment of superficial soft tissue metastasis: a 12-year retrospective analysis

Qiang,

Shi,

Sun

et al. 2024

Radiat Oncol

View full text Add to dashboard Cite

Background Superficial soft tissue metastasis (S-STM) of malignant tumors is uncommon and often brings great pain to patients. However, current treatment options are limited. The purpose of this study was to explore the clinical efficacy and prognostic factors of CT-guided radioactive iodine-125 (125I) seed implantation (RISI) for the treatment of S-STM. Methods We retrospectively evaluated 132 patients with S-STM who received RISI between June 2010 and July 2022. Local tumor progression-free survival (ltPFS), tumor response, pain control and complication were analyzed. The independent factors affecting ltPFS were screened out using a layered Cox proportional hazards model. Results The median follow-up time was 8.3 months (interquartile range [IQR], 4.5–15.3 months). The objective response rate (ORR) was 81.8%. The median ltPFS was 9.1 (95% CI: 6.6, 11.6) months. The Cox proportional hazard regression model revealed that the independent factors influencing ltPFS included KPS score, primary tumor, metastases, boundary, density and postoperative D90 (All P < 0.05). After RISI, the rate of pain relief was 92.3%. 66 (84.6%) patients reported pain marked relief, and 6 (7.7%) experienced pain moderate relief. No severe adverse events associated with RISI were observed during follow-up. Conclusions CT-guided RISI was associated with high local control and pain relief without severe adverse events and should be considered as a reliable palliative treatment modality for S-STM. Trial registration Trial registration Retrospectively registered.

show abstract

Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes

Cited by 8 publications

References 36 publications

125I brachytherapy: a useful treatment to control painful osteogenic bone metastases

125I brachytherapy: a useful treatment to control painful osteogenic bone metastases

Clinical efficacy of CT-guided 125I brachytherapy in patients with local residual or recurrent hepatocellular carcinoma after thermal ablation

Clinical efficacy and prognostic factors of CT-guided radioactive iodine-125 seed implantation for the treatment of superficial soft tissue metastasis: a 12-year retrospective analysis

Contact Info

Product

Resources

About